At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|October 28, 2022
Data point to “steady increase” in women matching into urology
Author(s)Urology Times staff
“The biggest finding is that we are seeing a steady increase in women representation in the field of urology,” says Teresa L. Danforth, MD.
Advertisement
In this video, Teresa L. Danforth, MD, discusses the background and notable findings from the study, “Closing the Gender Gap in the Urology Residency Match,” which was presented at the Northeastern Section of the American Urological Association Annual Meeting in Charlotte, North Carolina.
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5